In this fast-moving industry, BioCT keeps policy makers and influencers abreast of the latest developments and changing needs of the bioscience community.
Our mission is to provide education and advocacy for Connecticut’s bioscience and life science communities at the policy level and ensure synergy of action and alignment of state and federal initiatives that have a significant impact on our members.
The Government Affairs Committee is comprised of BioCT board members, industry executives and business advisors including the government relations firm of Rome, Smith & Lutz, which has deep expertise in matters impacting our industry.
President & CEO,
Todd Arnold, Ph.D.
Chief Laboratory Operations Officer,
Senior Manager, State Government Affairs,
Kathy Andrews Bilotas
Director of State Government Affairs,
Bill Claffey, J.D.
Partner, Tax Services,
Fiondella, Milone & LaSaracina
State Government Affairs, Regional Director,
Director, US Government Relations/Corporate Affairs,
Associate Vice President for Federal Relations,
Director, State Government Relations,
Senior Director, Government Relations,
University of Connecticut
Director, State Government Affairs and Public Policy,
Rome, Smith & Lutz
Regional Director, State Government Affairs,
Head of State Government Affairs,
Former State Representative
Director, Alliance Development
Rome Smith & Lutz
State Government Affairs Manager, East Coast,
On behalf of BIO, BioCT and our Board of Directors, as shown, we are writing in support of SB 1099, An Act Authorizing Bonds of the State for a Research Faculty Recruitment and Hiring Program by the University of Connecticut To Encourage the Creation of New Business Venture.
April 20, 2021
On behalf of BIO, BioCT and our Board of Directors, as shown, we are writing in support of SB 1094, An Act Authorizing Bonds of the State for CTNext and the Innovation Place Program.
February 10, 2021
Imposing arbitrary mandates on biopharmaceutical innovation can dry up investment into early stage companies who are innovators in the development of health solutions, and potentially risk lives.
January 5, 2021
Those workers involved in research, development and manufacturing of biopharmaceuticals and agricultural biotechnology products should be included in Phase 1B of the CDC’s Advisory Committee on Immunization Practices (ACIP) framework.
BioCT’s advocacy wins at the state level include:
Federal advocacy focuses on the continuing robustness of these agencies:
President & CEO